Five Myths About Ketamine and Matthew Perry’s Death (Fox News).
Through the first nine months of the year, global Johnson and Johnson's Spravato Ketamine nasal-spray revenues were $483 million, an 88.8% increase over the...
Psychedelic Happy Hour – Miami
Meet and Greet for Wonderland Miami Psychedelic Conference. November 10th.
Guests will enjoy cocktails, music, and plenty of networking with industry leaders in the psychedelics...
Psycheceutial Biosciences (BWVI) Listed on WeFunder!
Psycheceutical’s Psychedelic Experience, a Safer More Viable Choice in Getting Treated.
Imagine the benefits of psychedelics, without hallucinating!
Our Favorite small Psychedelic company Psycheceutical Bioscience is using...
Zappy Zapolin Hopes To Put Ibogaine Front And Center For Addiction
“The only legitimate addiction interrupter capable of breaking a heroin, meth, opiate, or alcohol addiction in a single 12-hour session.”
Known as the “Psychedelic Concierge...
Psycheceutical’s (BWVI) Delivery Tech is Grabbing Attention. Will Pharma Listen?
A startup’s psychedelic delivery tech is grabbing attention. Will pharma listen? PharmaVoice
Psycheceutical is developing a back-of-the-neck topical treatment for ketamine but believes the delivery...
COMPASS Pathways (CMPS) Announces Up to $285 Million Private Placement
Transaction led by healthcare specialist investors, TCGX and Aisling Capital
$125 million financing upfront with up to an additional $160 million tied to exercise of...
Billionaire, Point 72’s Steve Cohen, Continues to Support Psychedelic Research.
Cohen Psychedelic Research & Health Initiative
Cohen Foundation Awards $5 Million for MDMA Therapy Approval
Millions of Americans suffer from depression, anxiety, addiction, post-traumatic stress disorder...
Psycheceutical’s (BWVI) NeuroDirect™ Ketamine can Help Alleviate Headaches and Migraines Within Minutes, With no...
Photo MAPS Founder Rick Doblin visits Psycheceutical's Chief Visionary Officer Mike 'Zappy' Zapolin, CEO Chad Harman at the company's lab and tests NeuroDirect™ Ketamine....
Psycheceutical Bioscience (BWVI) Secures Funding for Clinical Trials
Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD.
Company raises $1.3M USD convertible note from Cantheon Capital for in-human trials...
Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating...
A pre-clinical observational study published in Drug Development & Delivery found that more than 80% of patients experienced relief within minutes of applying NeuroDirect™ ketamine topical...
Latest article
Adding BCM Resources Corporation (B.V) $0.27, Up 42%, to Watch List.
'Elephant Hunter' Dr. Sergei Diakov is Expanding Drill Footprint, to Outline a Potentially Massive Copper-Gold System Beneath the Surface.
Led by legendary geologist Dr. Sergei...
New Report on Sekur Private Data (SWISF). Palantir’s Open Secure AI.
Palantir CEO Alex Karp discusses open-weight artificial intelligence models, how he believes the technology should be regulated and why the U.S. should avoid Europe’s...
Replimune (REPL) Jumps 100%.
A Nifty $415 Million Gain (in an hour) for Shareholders.
Not out of the woods yet..
Short and to the point: We listened to whole meeting...
